RxDoctor Payments Data

Mohammad Latif Jangda, MD

Geriatric Psychiatry · Pembroke Pines, FLNPI 1407934912

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $507 of the $664 with a category attached, or 76.3%. 6 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 48.1% of the total.

$664in general payments, 2019–2025

Across 32 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$320
  • AbbVie$207
  • Alkermes, Inc.$80
  • Vanda Pharmaceuticals Inc.$31
  • Teva Pharmaceuticals USA, Inc.$16
  • Takeda Pharmaceuticals U.S.A., Inc.$12

What the payments were for

  • Food & beverage$50776%
  • Education$15824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$664 in reported general payments places this provider in the 65th percentile of 33 geriatric psychiatry providers in Florida.

See all geriatric psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$67,412
Medicare patients
143
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate30$240,646
VraylarCariprazine Hcl69$99,577
Abilify MaintenaAripiprazole18$56,178
RexultiBrexpiprazole26$48,020
TrintellixVortioxetine Hydrobromide83$47,375
Invega SustennaPaliperidone Palmitate18$37,418
VivitrolNaltrexone Microspheres20$37,249
Lurasidone Hcl36$20,715
Aripiprazole186$8,219
Ziprasidone Hcl19$7,044
Quetiapine Fumarate417$5,051
Olanzapine177$4,725
Divalproex Sodium ErDivalproex Sodium31$3,596
Clozapine80$3,406
Divalproex Sodium184$3,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$320$240,64630 claims
AbbVieVraylar$207$99,57769 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$12$47,37583 claims
Alkermes, Inc.Vivitrol$80$37,24920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 geriatric psychiatry providers in Florida.

Other geriatric psychiatry in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →